Abstract:BACKGROUND:In recent years, studies have demonstrated that polymorphisms in the promoters of Fas and FasL are significantly associated with breast cancer risk. However, the results of these studies were inconsistent. This case-control study was performed to explore the associations between Fas rs1800682 and FasL rs763110 polymorphisms and breast cancer.MATERIALS AND METHODS:A hospital-based case-control study of 560 Han Chinese females with breast cancer (583 controls) was conducted. The MassARRAY system was used to search for a possible association between the disease risk and the two single nucleotide polymorphisms, Fas rs1800682 and FasL rs763110. Statistical analyses were performed using SNPStats software to conduct Pearson's chi-square tests in five different genetic models. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated after adjustment to age and body mass index. PHASE v2.1 software was used to reconstruct all common haplotypes.RESULTS:A statistically significant association was found between Fas rs1800682 and increased breast cancer risk (AG vs AA: OR =1.37, 95% CI =1.06-1.78; AA+AG vs GG: OR =1.32, 95% CI =1.04-1.66), and also it was found that the FasL rs763110 polymorphism may decrease the risk. Stratified analyses demonstrated that the rs763110 polymorphism was associated with lower breast cancer risk among postmenopausal females (heterozygote model: OR =0.69, 95% CI =0.49-0.97; dominant model: OR =0.70, 95% CI =0.51-0.96). The T allele of rs763110 was also associated with a decreased risk of lymph node metastasis (allele model: OR =0.75, 95% CI =0.57-0.97) and an increased risk of the breast cancer being human epidermal growth factor receptor 2 positive (allele model: OR =1.37, 95% CI =1.03-1.18). Moreover, haplotype analysis showed that Ars1800682Trs763110 was associated to a statistically significant degree with lower risk of breast cancer (OR =0.70, 95% CI =0.53-0.91).CONCLUSION:These data suggest that the presence of Fas rs1800683 is an important risk factor for breast cancer, whereas FasL rs763110 may exert a protective effect against the onset of breast cancer.

Evaluation of the Effect of Menopausal Status and BMI on Polymorphisms in Fas/Fas L and the Risk of Breast Cancer

Distinct Role of the Fas Rs1800682 and FasL Rs763110 Polymorphisms in Determining the Risk of Breast Cancer among Han Chinese Females.

Follicle-stimulating hormone receptor gene polymorphisms influence Body Mass Index, metabolism, and bone mineral density in postmenopausal women

Functional Polymorphisms in Fas and Fasl Contribute to Increased Apoptosis of Tumor Infiltration Lymphocytes and Risk of Breast Cancer

FAS −1,377 G/A Polymorphism is Associated with Cancer Susceptibility: Evidence from 10,564 Cases and 12,075 Controls

FASL Rs763110 Polymorphism Contributes to Cancer Risk: an Updated Meta-Analysis Involving 43,295 Subjects.

Association Of The Polymorphisms In The Fas/Fasl Promoter Regions With Cancer Susceptibility: A Systematic Review And Meta-Analysis Of 52 Studies

Association Of Fas-1377 G/A Polymorphism With Susceptibility To Cancer

Genetic Polymorphisms in DNA Repair and Oxidative Stress Pathways May Modify the Association Between Body Size and Postmenopausal Breast Cancer

The Diplotype Fas −1377A/−670G As a Genetic Marker to Predict a Lower Risk of Breast Cancer in Chinese Women

Polycyclic Aromatic Hydrocarbons and Postmenopausal Breast Cancer: an Evaluation of Effect Measure Modification by Body Mass Index and Weight Change

Association Analysis of Interleukin-18 Gene Promoter Region Polymorphisms and Susceptibility to Sporadic Breast Cancer in Chinese Han Women.

Interactions Between RASA2, CADM1, HIF1AN Gene Polymorphisms and Body Fatness with Breast Cancer: a Population-Based Case-Control Study in China.

Functional Polymorphisms in FAS/FASL System Contribute to the Risk of Occurrence but Not Progression of Gastric Cardiac Adenocarcinoma.

Associations between Fas/FasL polymorphisms and susceptibility to cervical cancer: a meta-analysis

Genetic Polymorphisms of Insulin-Like Growth Factor 1 and Insulin-Like Growth Factor Binding Protein 3, Xenoestrogen, Phytoestrogen, and Premenopausal Breast Cancer.

BMI and breast cancer risk around age at menopause

Adiposity and breast, endometrial, and colorectal cancer risk in postmenopausal women: Quantification of the mediating effects of leptin, C-reactive protein, fasting insulin, and estradiol

[Association Between Fas/Fas L Genes Promoter Polymorphisms and Pathogenic Risk of Cervical Cancer].

Functional Polymorphisms in Cell Death Pathway Genes FAS and FAS Ligand and Risk of Prostate Cancer in a Chinese Population.

Effects of obesity on breast aromatase expression and systemic metabo-inflammation in women with BRCA1 or BRCA2 mutations